The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Open accessAbstract
mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humoral responses. Moreover, mRNAs have inherent adjuvant properties due to their complex interaction with pattern recognition receptors (PRRs). This recognition can be either beneficial in activating antigen-presenting cells (APCs) or detrimental by indirectly blocking mRNA translation. To decipher this Janus effect, we describe the different innate response mechanisms triggered by mRNA molecules and how each element from the 5' cap to the poly-A tail interferes with innate/adaptive immune responses. Then, we emphasize the importance of some critical steps such as production, purification, and formulation as key events to further improve the quality of immune responses and balance innate and adaptive immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”
From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [4]
In the citing paper
“The use of CleanCap® cap analogs reduces the probability of reverse capped, uncapped, and cap0 intermediates, and the co-transcribed mRNA only possesses a cap1 structure, therefore capping rate can be 90% or higher.52,126”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“The vaccinia capping enzyme (VCE) integrates the enzymatic activity of RTPase, GTase, and G-N7 MTase, which can be capped to generate a cap0 structure, and then 2′-O-MTase can be used to generate a methylated cap1 structure, thus reaching a capping efficiency of 100%.52”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“dsRNA can activate PRR such as TLR3,52,156 whereas ssRNA activates TLR7 and TLR8 to produce IFN-I, thus inducing inflammation in the host and interrupting mRNA translation.157,158”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Currently, nucleoside-modified mRNA vaccines employ 100% chemically modified nucleosides replacing natural nucleosides, and m1ψ is often used to replace uridine during IVT to improve the safety and stability of mRNA vaccines.52,134,172”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Uridine depletion to reduce counterproductive immune reactions can be achieved by the replacement of uridine by codon optimization, but this must be balanced with regard to transfer RNA abundance.120, 121, 122”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“The optimization of mRNA constructs, including the coding sequence, can regulate immunogenicity without incorporation of modified nucleosides.”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“Further, the 5′ cap protects the mRNA sterically from degradation by exonucleases, and it works synergistically with the poly(A) tail at the 3′ end, poly(A) binding proteins and translation initiation factor proteins to circularize mRNA and recruit ribosomes for initiating translation10,11.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“A sufficiently long tail (100–150 bp) is necessary to interact with poly(A) binding proteins that form complexes necessary for initiating translation11,12 and protecting the cap from degradation by decapping enzymes13.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“These engineered UTR sequences minimize mRNA degradation by excluding miRNA-binding sites11 and AU-rich regions in the 3′ UTR19.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Kato, H., Takeuchi, O., Mikamo, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., & Akira, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080091 · Cited by 1,649
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Flagged first, then by citations
1 of the 92 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 376
Wang, X., Zhong, Z., & Wang, W. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0011 · Cited by 13
Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine
Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12010057 · Cited by 13
Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside
Kenoosh, H. A., Pallathadka, H., Hjazi, A. M., Al‐Dhalimy, A. M. B., Zearah, S. A., Ghildiyal, P., Al‐Mashhadani, Z. I., Mustafa, Y. F., Hizam, M. M., & Elawady, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3954 · Cited by 15
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors
Wang, S., Xu, X., Viitala, T., Shu, Y., & Zhang, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102737 · Cited by 14
Research progress of mosquito-borne virus mRNA vaccines
Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11
An LNP-mRNA vaccine protects fish against rhabdovirus infection
Ayad, C., Porter, D., Lambert, E., Libeau, P., Coiffier, C., Ginet, V., Collet, B., Levraud, J., Boudinot, P., & Verrier, B. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126957 · Cited by 12
Self-citationThe dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
Song, J., Zhang, Y., Zhou, C., Zhan, J., Cheng, X., Huang, H., Mao, S., & Zong, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112037 · Cited by 10
Holland, D. A., Acevedo‐Skrip, J., Barton, J. R., Thompson, R., Bowman, A. M., Dewar, E. A., Miller, D. V., Zhao, K., Swartz, A. R., & Loughney, J. W. (2024) · Vaccines · doi:10.3390/vaccines12080899 · Cited by 10
The Bright Future of mRNA as a Therapeutic Molecule
Vélez, D. E., Torres, B. L., & Hernández, G. (2025) · Genes · doi:10.3390/genes16040376 · Cited by 11
EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma
Zhang, W., Wang, C., Meng, Y., He, L., & Dong, M. (2025) · Vaccines · doi:10.3390/vaccines13050478 · Cited by 10
Construction and immunogenicity of an mRNA vaccine against chikungunya virus
Liu, J., Lu, X., Li, X., Huang, W., Fang, E., Li, W., Liu, X., Liu, M., Li, J., Li, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129118 · Cited by 10
Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
Vajari, M. K., Sanaei, M., Salari, S., Rezvani, A., Ravari, M. S., & Bashash, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110696 · Cited by 10
Chen, K., Zhang, L., Fang, Z., Li, J., Li, C., Song, W., Huang, Z., Chen, R., Zhang, Y., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294288 · Cited by 10
Wang, S., Zhu, Z., & Li, J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01016 · Cited by 11
Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Lu, J., Wei, W., & He, W. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101700 · Cited by 9
Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 9
Guo, C., Tang, Y., Zeng, L., You, X., Luo, S., Du, Y., Wang, L., Wang, L., Wang, J., Chen, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202501628 · Cited by 9
The role of mRNA vaccines in infectious diseases: a new era of immunization
Batisani, K. (2025) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-025-00246-3 · Cited by 10
Zhang, Y., Li, J., Wang, Z., Kuang, Y., Li, S., & Wang, X. (2025) · Animal Diseases · doi:10.1186/s44149-025-00186-7 · Cited by 9
Chen, F., Ren, S., Huang, L., Wu, Q., Li, M., Li, S., Gao, J., Lai, Y., Cai, Z., Liu, X., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06028 · Cited by 9
Jo, S., Lee, J. S., Park, S., Kim, Y., Yoon, S., Lee, S., Cho, S., Cho, Y., Oh, A., Ha, D., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114471 · Cited by 9
RETRACTED ARTICLE: An overview on mRNA-based vaccines to prevent monkeypox infection
Natami, M., Gorgzadeh, A., Gholipour, A., Fatemi, S. N., Firouzeh, N., Zokaei, M., Ali, S. H. M., Kheradjoo, H., Sedighi, S., Gholizadeh, O., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02355-1 · Cited by 10
RetractedDeveloping Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Phan, T. X., Fan, D., & Melstrom, L. G. (2024) · Current Oncology · doi:10.3390/curroncol31090361 · Cited by 9
Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?
Gupta, R., Arora, K., Arora, N. M., & Kundu, P. K. (2024) · RNA Biology · doi:10.1080/15476286.2024.2399307 · Cited by 11
Zhang, S., Wang, X., Zhao, T., Yang, C., & Huang, L. (2025) · Vaccines · doi:10.3390/vaccines13010068 · Cited by 8
Immunotherapy for neuroblastoma using mRNA vaccines
Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 8
Vaccine approaches to treat urothelial cancer
Giudice, G. C., & Sonpavde, G. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2379086 · Cited by 9
Rosa, S. S., Nunes, D., Grinsted, J., Prazeres, D. M. F., Azevedo, A. M., Bracewell, D. G., & Marques, M. P. C. (2025) · Separation and Purification Technology · doi:10.1016/j.seppur.2025.132881 · Cited by 8
Vega‐Magaña, N., Muñóz-Valle, J. F., Rodríguez, M. P., Segura, O. V., Pereira-Suárez, A. L., Hernández‐Bello, J., & García‐Chagollán, M. (2022) · Vaccines · doi:10.3390/vaccines10071117 · Cited by 9
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
mRNA vaccines for prostate cancer: A novel promising immunotherapy
Tang, Y., Yi, X., & Ai, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189333 · Cited by 6
Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications
Zhao, P., Yang, Y., Yu, L., Li, G., & Zhu, D. (2025) · Gels · doi:10.3390/gels11060468 · Cited by 7
Yakovlev, V. A., Litvinova, V. R., Борисовна, Р. Н., Borgoyakova, M. B., Tigeeva, E. V., Starostina, E. V., Ivanova, K. I., Gudymo, A. S., Danilchenko, N. V., Perfilyeva, O. N., et al. (2025) · Vaccines · doi:10.3390/vaccines13080883 · Cited by 7
Kim, J. G., Xu, J., Lee, D., Song, J., Lee, S., Hong, M., Zhu, J., Zhu, A. T., Patwari, K., Shim, E.-H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c19036 · Cited by 8
Zhang, J., He, Q., Yan, X., Liu, J., Bai, Y., An, C., Cui, B., Gao, F., Mao, Q., Wang, J., et al. (2022) · MedComm · doi:10.1002/mco2.188 · Cited by 7
Zhu, J., He, C., Liu, Y. K., Chen, M., Zhang, J., Chen, D., Ni, H., & Wen, J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1472824 · Cited by 7
Zhang, X., Xu, W., Wang, Z., Liu, J., Gong, H., & Zou, W. (2024) · European journal of medical research · doi:10.1186/s40001-024-02191-x · Cited by 7
Precision therapeutic targets for HPV-positive cancers: an overview and new insights
Huang, Y., Wang, J., Yang, W., Hou, F., & Feng, X. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00641-7 · Cited by 7
Ayad, C., Yavuz, A., Salvi, J.-P., Libeau, P., Exposito, J., Ginet, V., Monge, C., Verrier, B., & Arruda, D. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061297 · Cited by 7
Self-citationEvaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens
Snoeck, J., Chiers, K., Tam, Y. K., Sanders, N. N., & Garmyn, A. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103078 · Cited by 7
Good Manufacturing Practices and Upscaling of mRNA Vaccine Production
Stamoula, Ε., Vavilis, T., Dardalas, I., & Papazisis, G. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch6 · Cited by 7
Che, S., Xue, F., Li, Z., Su, Z. G., Ma, G., Li, Z., Yu, A., Liu, M., & Zhang, S. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28560 · Cited by 6
Adhikary, K., Paul, A., Madan, A., Islam, A., Ashique, S., & Ramzan, M. (2025) · Advances in immunology · doi:10.1016/bs.ai.2024.10.011 · Cited by 6
Han, Y., Zhang, K., Xin, N., Gao, X., Ma, G., An, J., & Li, Y. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139025 · Cited by 6
Future prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 7
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Chen, G., Yu, X., Luo, L., Zhang, F., Dai, X.-H., Li, N., Shen, Z.-W., Wu, K.-Q., Lou, D., Peng, C.-G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.065 · Cited by 6
A (RP)UHPLC/UV analytical method to quantify dsRNA during the mRNA vaccine manufacturing process
Rosa, S. S., Zhang, S., Sari, Y., & Marques, M. P. C. (2024) · Analytical Methods · doi:10.1039/d4ay00560k · Cited by 6
Minnaert, A., Devoldere, J., Peynshaert, K., Vercruysse, L., Smedt, S. C. D., & Remaut, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010074 · Cited by 6
Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA
Ulmer, J. B., & Liu, M. A. (2021) · Molecular Frontiers Journal · doi:10.1142/s2529732521400022 · Cited by 6
Modern vaccine strategies for emerging zoonotic viruses
Ahmed, A., Safdar, M., Sardar, S., Yousaf, S., Farooq, F., Raza, A., Shahid, M., Malik, K. A., & Afzal, S. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148660 · Cited by 6
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine
Zhao, J., Xiao, P., Xin, A., Zhu, H., Wang, H., Xiao, J., & Gao, H. X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1503191 · Cited by 5
Li, F., Wang, D., Gao, Y., & Cui, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648698 · Cited by 6
mRNA vaccines for porcine reproductive and respiratory syndrome: A new paradigm in swine health
Khan, M., Taira, O., Shi, X., Wang, H., & Cai, X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152950 · Cited by 5
Morreel, K., t’Kindt, R., Debyser, G., Jonckheere, S., & Sandra, P. J. F. (2022) · LCGC Europe · doi:10.56530/lcgc.eu.jk3969w4 · Cited by 5
Hu, J., Yuan, Z., Jiang, Y., & Mo, Z. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020359 · Cited by 5
RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives
Xing, L., Wang, Z., Li, D., Li, J., & Liu, M. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.25 · Cited by 6
Bishani, A., Meschaninova, M. I., Аркадьевна, З. М., & Chernolovskaya, E. L. (2024) · Molecules · doi:10.3390/molecules29133225 · Cited by 5
The Recent Research Progress of the Tumor mRNA Vaccine
Zhao, H., Li, M., Zhou, J., Hu, L., Lu, S., & Li, P. (2024) · Vaccines · doi:10.3390/vaccines12101167 · Cited by 5
Lipid-based nanoparticles and their recent advances
Sujeevan, O. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.18.3.0096 · Cited by 5
Fattahi, N., Khoshnood, S., Omidi, N., & Kalani, B. S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144311 · Cited by 5
Advances in mRNA vaccines for viral diseases
Huang, Y., Zhu, X., Guo, X., Zhou, Y., Liu, D., Mao, J., Xiong, Y., Deng, Y., & Gao, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28924 · Cited by 5
Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside
Al‐Hawary, S. I. S., Jasim, S. A., Hjazi, A. M., Oghenemaro, E. F., Kaur, I., Kumar, A., Al‐Ani, A. M., Alwaily, E. R., Redhee, A. H., & Mustafa, Y. F. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3978 · Cited by 4
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms
Pazoki, A., Dadfar, S., Alirezaee, A., Oksenych, V., & Haghmorad, D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1617352 · Cited by 4
Immunotherapy for tuberculosis: current strategies and future directions
Lyu, M., Lai, H.-L., Peng, H., Luo, H., Zhou, J., Ma, W.-A.-Q., Zhang, C., Ruan, H., Liu, Y., Chen, J., et al. (2025) · Military Medical Research · doi:10.1186/s40779-025-00655-7 · Cited by 4
Zhao, K., Raffaele, J., Holland, D. A., Feibelman, K. M., Lengel, K., Shanter, J., & Wen, E. P. (2026) · Biotechnology Progress · doi:10.1002/btpr.70109 · Cited by 4
Dahm, G. C., Pieper, M., Schepers, H., & Rentmeister, A. (2026) · ChemMedChem · doi:10.1002/cmdc.202500826 · Cited by 6
Exploring the role of cationic lipids in modulating immunogenicity and vaccine efficacy of mRNA-LNP
Zhou, Y., Shan, X., Gu, R., Xia, Y., & Huang, X. (2024) · Particuology · doi:10.1016/j.partic.2024.11.011 · Cited by 4
Hong, Y., Liu, Y., Shen, H., Li, B., & Li, Q. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06344-2 · Cited by 5
Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses
Albadr, R. J., Sameer, H. N., Athab, Z. H., Adil, M., Yaseen, A., & Allela, O. Q. B. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00269-2 · Cited by 4
Cellular reprogramming: Mathematics meets medicine
Dotson, G. A., Ryan, C. W., Chen, C., Muir, L. A., & Rajapakse, I. (2020) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1515 · Cited by 4
Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development
Cholkar, S. S., Gawade, A. R., & Kuchekar, A. B. (2022) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2979 · Cited by 4
Lin, G., & Zhang, Y. (2023) · Biotechnology Letters · doi:10.1007/s10529-023-03379-7 · Cited by 4
Zhang, Y., Chen, Y., Lu, L., Xie, X., Ren, H., Wu, L., Tan, L.-N., Xu, T., & Jin, Y. J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673275752231219080500 · Cited by 4
The Use of Medicinal Plant Extract in Hand Sanitizer and Spray to Combat Against Covid-19
Cholkar, S. S., Gawade, A. R., & Kuchekar, A. B. (2022) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2977 · Cited by 4
Chen, J., Cen, Q., Hu, R., Qiu, Y., Zhang, H., Wang, H., Hu, Y., Xie, X., & Li, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144766 · Cited by 3
Qiu, K., Mao, M., Song, Y. H., Duan, X., Rao, Y., Feng, L., Cheng, D., Shao, X., Liang, Y., Jiang, C., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102780 · Cited by 3
Single-step recovery of mRNA via multimodal chromatography to advance vaccine manufacturing
Rosa, S. S., Stibbs, D. J., Couto, P. S., Prazeres, D. M. F., Azevedo, A. M., Bracewell, D. G., & Marques, M. P. C. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466610 · Cited by 3
mRNA Vaccines for Cancer Treatment
Torphy, R. J., Balachandran, V., & Soares, K. C. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.006 · Cited by 3
Albargy, H. A., & Othman, A. A. (2026) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2026.137 · Cited by 3
Zhang, Y., Zhang, J.-P., & Zhang, X.-B. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1838589 · Cited by 3
Harnessing dendritic cells as immunological bridges to potentiate mRNA cancer vaccines
Wu, R., Li, H., Li, Z., Hao, K., & Tian, H. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00995b · Cited by 3
Pioneering next-generation mRNA therapeutics through molecular engineering and delivery optimization
Qi, L., Li, Z., Feng, Z., Liu, J., & Chen, X. S. (2025) · Materials Today · doi:10.1016/j.mattod.2025.08.023 · Cited by 3
Nanocarrier-enabled STING agonist delivery for enhanced cancer immunotherapy
Wu, Y., & Liu, Q. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01643f · Cited by 4
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie · doi:10.1002/ange.202100352 · Cited by 3
Verma, A., & Awasthi, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128296588240321072042 · Cited by 3
Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation
Geng, K., Rice-Boucher, P. J., Kashentseva, E. A., Dmitriev, I. P., Lu, Z. H., Goedegebuure, S. P., Gillanders, W. E., & Curiel, D. T. (2023) · Viruses · doi:10.3390/v15112277 · Cited by 3
Corticosteroids and mRNA Vaccines: A Word of Caution
Zhong, Z., Combes, F., & Sanders, N. N. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.029 · Cited by 3
Snoeck, J., Cui, X., Vervaeke, P., Sanders, N. N., & Garmyn, A. (2026) · Veterinary Quarterly · doi:10.1080/01652176.2025.2603307 · Cited by 2
mRNA vaccines transform personalized lung cancer treatment
Wei, K., Wan, Z., Wen, M., Xin, S., Zhou, Y., Wei, J. C., Zhu, J., Tang, C., Xiong, Y., Jiang, T., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1707654 · Cited by 2
Comparison of Immune Cell Transfection by Different Vaccine Vectors After Intradermal Injection
Liu, J., Hinson, D. T., Hansen, M. A., Keulen, V. P. V., Parrett, B. J., Pease, L. R., & Barry, M. A. (2026) · Vaccines · doi:10.3390/vaccines14020185 · Cited by 2
Zhang, K., Liu, C., Ge, R., Zhang, Z., Liu, Q., Mo, O., Li, X., Liu, X., Li, H., & Hao, P. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114740 · Cited by 2
Qiao, N., Chen, J., Liu, Y., Chen, Z. J., & Chen, S. J. (2026) · MedScience · doi:10.1007/s11684-026-1210-6 · Cited by 3
Confronting the known unknown: historical lessons and future strategies for Disease X
Xiang, Y. H., Sun, G., Xiang, P., Hu, J., Tian, L., Zhang, Q., Wang, J., & Xie, C. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1833807 · Cited by 2
Advances and Challenges in Nanodelivery Systems for RNA Vaccines
Li, H., Zhao, Y., Yang, J., Guo, J., Cai, H., & Tong, A. (2026) · ACS Nano · doi:10.1021/acsnano.6c10327 · Cited by 2
Nanovaccines delivery approaches against infectious diseases
Tabarzad, M., Mohit, E., & Ghorbani‐Bidkorbeh, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00002-6 · Cited by 2
Tsou, H., Chang, C.-C., Maeda, T., & Lin, C. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_18 · Cited by 2
Meyer, R. A., Trabulo, S. M. D., Douthwaite, J. A., & Santos, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_1 · Cited by 3
Bafleh, W. S., Abdulsamad, H. M. R., Al-Qaraghuli, S. M., Khatib, R. Y. E., Elbahrawi, R. T., Abdukadir, A. M., Alsawae, S. M., Dimassi, Z., Hamdan, H., & Kashir, J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198848 · Cited by 2
Metadata
- Authors
- Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B.
- Affiliations
- Lyon 1 Université (FR)
- Corresponding author
- Verrier, Bernard
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 26
- Issue
- 3
- Pages
- 311-323
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2986812831
- Cited by
- 376
- References
- 92
- Citations by year
- 2026: 43 · 2025: 67 · 2024: 65 · 2023: 69 · 2022: 76 · 2021: 47 · 2020: 9
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Trends in Molecular Medicine (acceptedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- EuroNanoMed III
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Fondation Mérieux
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- mRNA vaccines, innate immune response, adaptive immune response, pattern recognition receptors, antigen-presenting cells, 5' cap, poly(A) tail, mRNA translation inhibition, vaccine formulation
- MeSH terms
- mRNA Vaccines, Animals, Humans, Immunity, Innate, RNA, Messenger, Vaccines, Synthetic, Receptors, Pattern Recognition, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
